Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 7:58 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Mesa Laboratories, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 216 | 219 | 184 | 134 | 118 |
Cost Of Goods | 83 | 85 | 75 | 47 | 53 |
Gross Profit | 133 | 134 | 109 | 87 | 65 |
Selling & Adminstrative & Depr. & Amort Expenses | 405 | 130 | 104 | 75 | 57 |
Income After Depreciation & Amortization | -272 | 3 | 5 | 12 | 7 |
Non-Operating Income | 2 | 1 | 3 | -2 | 1 |
Interest Expense | 6 | 5 | 4 | 8 | 6 |
Pretax Income | -276 | 0 | 4 | 2 | 3 |
Income Taxes | -21 | -1 | 2 | -1 | 2 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -254 | 1 | 2 | 3 | 1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -254 | 1 | 2 | 3 | 1 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 8 | 37 | 37 | 35 | 33 |
Depreciation & Amortization (Cash Flow) | 280 | 34 | 33 | 23 | 25 |
Income After Depreciation & Amortization | -272 | 3 | 5 | 12 | 7 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 5.39 | 5.36 | 5.34 | 5.12 | 4.37 |
Diluted EPS Before Non-Recurring Items | 7.17 | 5.55 | 4.96 | 5.24 | 4.21 |
Diluted Net EPS (GAAP) | -47.20 | 0.17 | 0.35 | 0.64 | 0.31 |
Fiscal Year end for Mesa Laboratories, Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 58.17 | 58.90 | 53.47 | 53.17 | 50.65 |
Cost Of Goods | 20.92 | 22.35 | 20.07 | 21.06 | 19.46 |
Gross Profit | 37.25 | 36.56 | 33.40 | 32.11 | 31.18 |
SG&A, R&D, and Dept/Amort Expenses | 31.67 | 307.84 | 33.47 | 32.17 | 31.85 |
Income After SG&A, R&D, and Dept/Amort Expenses | 5.58 | -271.28 | -0.07 | -0.06 | -0.67 |
Non-Operating Income | 1.17 | -2.16 | 3.87 | -0.36 | 0.78 |
Interest Expense | 2.84 | 1.89 | 1.86 | 0.91 | 1.05 |
Pretax Income | 3.91 | -275.33 | 1.95 | -1.33 | -0.94 |
Income Taxes | 0.52 | -20.75 | -0.17 | -0.10 | -0.39 |
Minority Interest | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 3.39 | -254.58 | 2.12 | -1.23 | -0.55 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 3.39 | -254.58 | 2.12 | -1.23 | -0.55 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 5.42 | 5.39 | 5.40 | 5.39 | 5.37 |
Diluted EPS Before Non-Recurring Items | 2.29 | 2.25 | 1.46 | 1.32 | 1.22 |
Diluted Net EPS (GAAP) | 0.62 | -47.26 | 0.39 | -0.23 | -0.10 |